Optimising a High Efficacy Plasmodium vivax Malaria Vaccine

优化高效间日疟原虫疟疾疫苗

基本信息

批准号：
10080950
负责人：
金额：
$ 90.65万
依托单位：
LONDON SCH OF HYGIENE & TROPIC. MEDICINE
依托单位国家：
英国
项目类别：
EU-Funded
财政年份：
2023
资助国家：
英国
起止时间：
2023 至无数据
项目状态：
未结题

来源：
https://gtr.ukri.org/projects?ref=10080950
关键词：
Optimising Efficacy Plasmodium vivax Malaria

项目摘要

Plasmodium vivax is the most widespread human malaria with 2.5 billion people living at risk in Africa, South America, Oceania and Asia. The revised Malaria Vaccine Technology Roadmap to 2030 recognises the severity of P. vivax malaria, calling for a vaccine intervention to achieve 75% efficacy over two years, now equally weighted with P. falciparum. However, if this ambition is to be realised, new and innovative approaches are urgently required to accelerate next-generation vaccine research and development, whilst the few known candidate antigens need to undergo early-phase clinical assessment. Here, we build on exciting breakthroughs in P. vivax vaccine research, recently pioneered in Europe, including new transgenic parasite technologies for functional assay development and production of a parasite clone that is safe for use in controlled human malaria infection (CHMI) clinical models. The Objectives of OptiViVax will integrate ambitious multi-disciplinary scientific and clinical approaches around the parasite’s lifecycle and will use our increased knowledge of P. vivax immuno-biology to further develop next-generation vaccines with improved efficacy. We will diversify the portfolio of new antigens ready for clinical testing by reverse vaccinology and diversify their delivery with new platforms and adjuvants developed using sustainable and improved GMP bio-manufacturing know-how. In parallel, the efficacy of known leading antigens will be benchmarked for the first time using innovative design of clinical studies and CHMI models making these lead candidate vaccines ready for future field trials. Improved preclinical functional assays, using state-of-the-art transgenic parasite lines, will also allow for mechanisms of antibody-mediated protection to be deciphered. The availability of new functional assays and human challenge models will underpin the future framework for informed decision making by the clinical vaccine community, policy makers, funders and regulators.

疟原虫是最广泛的人类疟疾，在非洲，大洋洲和ASIAL中有25亿人的疾病，芳香疫苗技术路线图。然而，如果要采用这种野心，则需要新的和创新的野心，以加速下一代疫苗的疫苗研发早期临床评估。 Optivax的目标将围绕Pa Rasite的生命周期纳入宽容的多学科科学和临床，并将开发出对Vivax Imuno-Biogy的知识，以进一步发展下一代，我们将改善Fficacy。通过现成的疫苗学测试，并通过可持续的GMP生物制造专有技术进行新的特征和佐剂进行多样化。准备未来的疫苗。和监管机构。